60 seconds Rapid Point-of-Care Diagnostics for CoVID19 using a novel multiplexed immuno-biosensor #esante #hcsmeufr #digitalhealth #Coronavirus #covid-19 #COVID19FR #coronavirusfrance
Une intelligence artificielle pour mieux ventiler les patients en réanimation #esante #hcsmeufr #digitalhealth #Coronavirus #covid-19 #COVID19FR #coronavirusfrance
16/04/2020
L’UE déconseille la géolocalisation dans l’usage d’apps mobiles de traçage des contacts #esante #hcsmeufr #digitalhealth #Coronavirus #covid-19 #COVID19FR #coronavirusfrance
17/04/2020
Using a novel multiplexed immuno-biosensor, Hememics is trying to provide a rapid detection solution of COVID-19 anywhere in the world. Rapid, cost-effective and real-time biomarker measurements are essential for quick and effective diagnosis and treatment of emerging diseases like COVID-19.
Hememics has developed a diagnostic test platform that can yield sensitive, selective, and measurable signals in response to specific antibodies and antigens in 60 seconds or less, with a single nasal swab or drop of blood. Testing is simple and could be administered by any health care worker, anywhere: ambulances, emergency rooms, community clinics, and makeshift hospitals.
Most importantly, this Bluetooth® connected technology transmits the test results to a cloud-based data management network, enabling real-time geographical alerts of outbreaks or travel screening at airports, borders, and transportation terminals.
The multiplex chip device can simultaneously detect up to 17 pathogens from blood or nasal swab.
Source: www.hememics.com
